男性不孕市场、机会、成长动力、产业趋势分析与预测，2024-2032

在人们对先进治疗方案的认识和获取不断增加的推动下，全球男性不孕症市场从 2024 年到 2032 年的复合年增长率预计将达到 4.7%。不孕症在全世界日益受到关注，影响了全球约 15% 的夫妇。据世界卫生组织 (WHO) 称，其中近一半的病例是由男性不孕症引起的，这导致对有效治疗解决方案的需求激增。

人们对男性不孕症问题的认识不断提高，加上诊断技术和治疗方法的进步，预计将推动市场扩张。此外，社会向晚育的转变以及人们对生育治疗的日益接受，进一步增加了对男性不孕症解决方案的需求。

整个男性不孕症产业根据测试、配销通路和地区进行分类。

在药物、手术介入和辅助生殖技术 (ART) 等各种治疗选择的推动下，治疗领域将在 2024 年至 2032 年期间经历显着增长。其中，胞浆内单一精子注射 (ICSI) 和体外受精 (IVF) 等 ART 手术因其高成功率而越来越多的采用。荷尔蒙疗法和基因编辑技术等创新疗法的发展也促进了这一领域的成长。随着越来越多的男性寻求克服不孕症挑战的解决方案，治疗领域预计将占据相当大的市场份额。

到 2032 年，由于人们越来越偏好便利且谨慎的购买选择，线上药局预计将在男性不孕症市场中获得显着份额。电子商务平台的激增和数位健康咨询的成长趋势使患者可以更轻鬆地在舒适的家中获得生育治疗和药物。网上药局提供各种生育产品，通常价格具有竞争力，并且还提供送货上门服务的额外好处。这种向线上购买的转变在无法获得专业生育诊所的地区尤其重要，为患者提供了可靠且方便的不孕症治疗选择。

由于其先进的医疗基础设施、高意识水平和支持性政府倡议，欧洲将在 2024 年至 2032 年期间推动男性不孕症市场取得可观的进展。该地区对生殖健康的高度重视，加上对研发的大量投资，正在促进不孕症治疗的创新。此外，欧洲领先的製药公司和生育诊所的存在也有助于尖端治疗方法的广泛应用。随着越来越多的男性因不孕症寻求医疗援助，在有利的监管环境和整个地区对生育治疗的接受度不断提高的支持下，欧洲市场必将经历大幅增长。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 诊断技术的进步
    • 辅助生殖科技的发展
    • 加强生育治疗的研究与开发
    • 提高意识和教育
  • 产业陷阱与挑战
    • 治疗费用高
    • 副作用和併发症
• 成长潜力分析
• 监管环境
• 技术景观
  • 核心技术
  • 邻近技术
• 2023 年定价分析
• 未来市场趋势
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司市占率分析
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 战略仪表板

第 5 章：市场估计与预测：按类型，2021 - 2032

• 主要趋势
• 测试
  • DNA片段化技术
  • 氧化压力分析
  • 显微镜检查
  • 精子凝集
  • 电脑辅助精液分析
  • 精子穿透试验
  • 其他测试
• 治疗
  • 药物
  • ART 和精索静脉曲张手术试剂和套件

第 6 章：市场估计与预测：按配销通路，2021 - 2032 年

• 主要趋势
• 医院药房
• 零售药局和药局
• 网路药局

第 7 章：市场估计与预测：按地区划分，2021 - 2032 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
  • 欧洲其他地区
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地区
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋
  • 中东和非洲其他地区

第 8 章：公司简介

• Andrology Solutions
• ASKA Pharmaceutical Co., Ltd.
• AdvaCare Pharma
• Bayer AG
• CinnaGen Co.
• CaerusBiotech
• Endo International plc
• HalotechDNA
• Intas Pharmaceuticals Ltd.
• Merck KGaA
• Sanofi
• SCSA Diagnostics, Inc
• The Cooper Companies, Inc.
• Vitrolife Group
• Zydus Lifesciences Limited

The Global Male Infertility Market is poised to exhibit 4.7% CAGR from 2024 to 2032, driven by increasing awareness and access to advanced treatment options. Infertility is a growing concern worldwide, affecting an estimated 15% of couples globally. According to the World Health Organization (WHO), male infertility contributes to nearly half of these cases, leading to a surge in demand for effective treatment solutions.

The rising awareness of male infertility issues, coupled with advancements in diagnostic techniques and treatment methods, is expected to propel market expansion. Additionally, societal shifts towards later parenting and the growing acceptance of fertility treatments are further bolstering the demand for male infertility solutions.

The overall Male Infertility Industry is classified based on the test, distribution channel, and region.

The treatment segment will experience significant growth over 2024-2032, driven by the availability of various therapeutic options, including medications, surgical interventions, and assisted reproductive technologies (ART). Among these, ART procedures such as intracytoplasmic sperm injection (ICSI) and in vitro fertilization (IVF) are witnessing increasing adoption due to their high success rates. The development of innovative treatments, such as hormonal therapies and gene editing techniques, is also contributing to the growth of this segment. As more men seek solutions to overcome infertility challenges, the treatment segment is expected to capture a substantial share of the market.

Online pharmacies are set to gain a notable share in the Male Infertility Market by 2032, driven by the increasing preference for convenient and discreet purchasing options. The proliferation of e-commerce platforms and the growing trend of digital health consultations are making it easier for patients to access fertility treatments and medications from the comfort of their homes. Online pharmacies offer a wide range of fertility products, often at competitive prices, along with the added benefit of home delivery services. This shift towards online purchasing is particularly significant in regions with limited access to specialized fertility clinics, providing patients with a reliable and accessible option for managing their infertility treatment.

Europe will drive commendable gains in the Male Infertility Market throughout 2024-2032, owing to its advanced healthcare infrastructure, high awareness levels, and supportive government initiatives. The region's strong focus on reproductive health, coupled with significant investment in research and development, is fostering innovation in infertility treatments. Additionally, the presence of leading pharmaceutical companies and fertility clinics in Europe is contributing to the widespread availability of cutting-edge treatments. With a growing number of men seeking medical assistance for infertility issues, the European market is set to experience substantial growth, supported by favorable regulatory environments and increasing acceptance of fertility treatments across the region.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Advancements in diagnostic technologies
    • 3.2.1.2 Growth in assisted reproductive technologies
    • 3.2.1.3 Increasing research and development in fertility treatments
    • 3.2.1.4 Rising awareness and education
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of treatment
    • 3.2.2.2 Side effects and complications
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technological landscape
  • 3.5.1 Core technologies
  • 3.5.2 Adjacent technologies
• 3.6 Pricing analysis, 2023
• 3.7 Future market trends
• 3.8 Porter's analysis
• 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Test
  • 5.2.1 DNA fragmentation technique
  • 5.2.2 Oxidative stress analysis
  • 5.2.3 Microscopic examination
  • 5.2.4 Sperm agglutination
  • 5.2.5 Computer assisted semen analysis
  • 5.2.6 Sperm penetration assay
  • 5.2.7 Other tests
• 5.3 Treatment
  • 5.3.1 Medication
  • 5.3.2 ART and varicocele surgery reagents and kits

Chapter 6 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Hospitals pharmacies
• 6.3 Retail pharmacies and drug stores
• 6.4 Online pharmacies

Chapter 7 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 UK
  • 7.3.3 France
  • 7.3.4 Spain
  • 7.3.5 Italy
  • 7.3.6 Netherlands
  • 7.3.7 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 Japan
  • 7.4.3 India
  • 7.4.4 Australia
  • 7.4.5 South Korea
  • 7.4.6 Rest of Asia Pacific
• 7.5 Latin America
  • 7.5.1 Brazil
  • 7.5.2 Mexico
  • 7.5.3 Argentina
  • 7.5.4 Rest of Latin America
• 7.6 Middle East and Africa
  • 7.6.1 South Africa
  • 7.6.2 Saudi Arabia
  • 7.6.3 UAE
  • 7.6.4 Rest of Middle East and Africa

Chapter 8 Company Profiles

• 8.1 Andrology Solutions
• 8.2 ASKA Pharmaceutical Co., Ltd.
• 8.3 AdvaCare Pharma
• 8.4 Bayer AG
• 8.5 CinnaGen Co.
• 8.6 CaerusBiotech
• 8.7 Endo International plc
• 8.8 HalotechDNA
• 8.9 Intas Pharmaceuticals Ltd.
• 8.10 Merck KGaA
• 8.11 Sanofi
• 8.12 SCSA Diagnostics, Inc
• 8.13 The Cooper Companies, Inc.
• 8.14 Vitrolife Group
• 8.15 Zydus Lifesciences Limited